Levetiracetam as Adjunctive Therapy for Refractory Anxiety Disorders
The DOI matches its Crossref record.
Abstract
BACKGROUND: Anxiety disorders are the most prevalent psychiatric disorders as a group, and despite the effectiveness of currently available treatments for anxiety, many patients (40%-65%) remain symptomatic after initial intervention. Thus, there is a significant need for efficacious pharmacologic agents that are safe and well tolerated and lead patients to remission of symptoms. We present a retrospective analysis that assessed the efficacy and tolerability of adjunctive levetiracetam, a novel anticonvulsant agent, in the treatment of refractory anxiety. METHOD: Forty patients with DSM-IV anxiety disorders, who were deemed partial responders or nonresponders to anxiolytic therapy, received adjunctive levetiracetam in a naturalistic fashion during the time period from January 2004 through December 2004. We conducted a retrospective chart review. The primary outcome measures were the Clinical Global Impressions-Severity of Illness (CGI-S) scale and the Clinical Global Impressions-Improvement (CGI-I) scale. Mean change from baseline to endpoint was assessed using 2-tailed paired t tests. RESULTS: Levetiracetam at a mean +/- SD dose of 1969 +/- 819 mg/day for a mean +/- SD time period of 9.3 +/- 5.1 weeks was generally well tolerated. Patients were markedly ill with a mean +/- SD baseline CGI-S score of 6.2 +/- 0.6. Patients improved significantly, with an endpoint CGI-S score of 4.2 +/- 1.8 (p < .001) and CGI-I score of 2.6 +/- 1.2. Adverse events were generally mild, and only 4 patients discontinued levetiracetam because of side effects. CONCLUSION: These preliminary data suggest that levetiracetam may be an effective adjunctive treatment for patients with anxiety disorders who remain symptomatic despite initial anxiolytic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164
“…of epilepsy (for review, see De Smedt et al., 2007), and which also shows promise for the treatment of anxiety disorders (Zhang et al., 2005; Kinrys et al., 2006, 2007), pain (Price, 2004; Dunteman, 2005; Enggaard et al., 2006), dyskinesias (McGavin et al., 2003; Bushara et al., 2005;…”
BackgroundSV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138
Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Nowack, A., Malarkey, E. B., Yao, J., Bleckert, A., Hill, J., & Bajjalieh, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029560 · Cited by 81
“Currently marketed as KeppraH, levetiracetam is FDA-approved for the treatment of epilepsy (reviewed in [1]), though it also shows promise in the treatment of anxiety disorders [2,3,4], pain [5,6,7], dyskinesias [8,9,10,11,12], and post-traumatic stress disorder [3].”
BackgroundAligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“…2012; Simon et al., 2009), four retrospective cohorts (Bakish et al., 1995; Cowley, Ha, & Roy‐Byrne, 1997; Durham, Higgins, Chambers, Swan, & Dow, 2012; Kinrys et al., 2007), one prospective cohort (Milrod et al., 2016), three case series (Aarre, 2003; Otto, Pollack, Penava, & Zucker, 1999; Tesar…”
Using the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments
Saxena, A., Paredes-Echeverri, S., Michaelis, R., Popkirov, S., & Perez, D. L. (2022) · Seminars in Neurology · doi:10.1055/s-0041-1742145 · Cited by 53
Metadata
- Authors
- Kinrys, G., Worthington, J. J., Wygant, L., Nery, F., Reese, H., & Pollack, M. H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-07-15
- Volume
- 68
- Issue
- 07
- Pages
- 1010-1013
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2042233685
- Cited by
- 22
- References
- 0
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.